Heidelberg Pharma (HPHA) Q4 2024 earnings summary

Executive summary

• Expanded executive team with new CFO and CEO appointments in 2023 and early 2024.

• Achieved significant progress in clinical pipeline, notably with HDP101 showing promising efficacy and safety, including a complete response in a heavily pretreated patient.

• Amended royalty agreement with Healthcare Royalty, securing substantial non-dilutive financing and extending cash runway into 2027.

• Out-licensed legacy asset TLX250 CDX advanced to FDA priority review, with potential market launch expected in H2 2025.

• Patent granted for Amanitin-based ADC technology platform, strengthening IP position.

Financial highlights

• Sales revenue and other income: €16.8M in 2023, €12M in 2024, reflecting lower partnership monetization.

• Net loss: €21.2M in 2023, improving to €19.4M in 2024; basic loss per share improved to -€0.42.

• Cash at year-end: €43.4M in 2023, €29.4M in 2024, reflecting business outflows and loan repayments.

• Operating expenses: €38.0M in 2023, €32.6M in 2024; R&D costs remained the largest expense.

• Financing cash flow improved to an inflow of €22.8M, driven by the HCRX transaction.

Outlook and guidance

• FY2025 sales revenue and other income expected between €9M and €11M; operating expenses projected at €40M–€45M.

• EBIT for 2025 forecasted at -€30M to -€35M, excluding FX effects.

• Anticipated cash inflow of €50M–€55M in 2025, mainly from milestone payments, supporting funding into 2027.

• HDP101 Phase IIa to start later in 2025; HDP102 first patient dosing imminent; HDP103 clinical trial application planned for late 2025.

• Guidance to be updated as R&D plans evolve.